Regulatory T cells, tumour immunity and immunotherapy

By W. Zou. Nature reviews. Immunology, 2006

2,206 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/1adf7bf99cf0b80a0974d2360328eec1ab30ca8d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. W. Zou
2. Lieping Chen
3. D. Munn
4. D. Pardoll
5. A. Mellor
6. Hua Yu
7. R. Jove
8. H. Nishikawa

Citations in the corpus

• Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “As such they have the potential to increase the immune response to tumours, which is suppressed in many cancer patients through various mechanism”
• B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma (2006, background): “Human T reg cells (26, 47) disable TAA-specifi c T cell immunity (5, 27).”
• Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? (2009, background): “iTreg Cells and Cancer It has become evident that Foxp3 Treg cells are one of the main if not the main barrier to the implementation of cancer immuno therapies (Curiel, 2008; Zou, 2006).”
• Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer (2008, background): “Evidence indicates that cancer cells escape from immune responses through suppressive T reg -cell activit”
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. (2007, background): “This important finding thus linked IDO to the potent Treg system, which is known to be a key mechanism of immunosuppression in tumorbearing hosts (12).”
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies. (2015, background): “[22] Zou W.”
• Engineering T cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors (2016, neutral): “This is especially true in cancer where T cells can be pushed into a suppressive phenotype, hampering the immune response and leading to tumor expansion (Amarnath et al., 2011; Zou, 2006).”
• Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans (2013, background): “Discussion Accumulating evidence indicates that effective cancer immunotherapy needs to control FOXP3 Treg cells naturally present in the immune system and abundantly infiltrating into tumor tissues (10, 11, 30).”
• Molecular Mechanisms of Treg-Mediated T Cell Suppression (2012, background): “However, Tregs can also dampen immune responses against tumors, as described for various types of cancer (Zou, 2006; Curiel, 2008).”
• STATs in cancer inflammation and immunity: a leading role for STAT3 (2009, positive): “, which promote tumour progression by inhibiting anti-tumour immune responses that are mediated by T H 1-type CD4 + T cells and CD8 + T cell”
• Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. (2007, background): “…as noted above, several different mechanisms are potentially rele- vant for Treg cell-mediated immune suppression, includ- ing cytokine-mediated (e.g., TGF-b, IL-10) as well as cell-surface molecule-dependent inhibition of T cells and APCs (e.g., GITR and CTLA4) (von Boehmer, 2005; Zou, 2006).”